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Until recently, mutagenicity testing was done on preselected compounds in a manner in which the
testing laboratories knew the identity of the substances under test and the "expected" results, i.e.,
positive for compounds selected because oftheir carcinogenicity and negative for food additives. There is
no completed study in which substances were tested blind using a standardized protocol. Also, little
attention has been placed on reproducibility and variability within and between laboratories. These
aspects are currently under investigation in microbial systems by NCI but the results will not be available
for 1-2 years.
In the NIEHS testing program a large number ofsubstances will be tested in a blind study. At present
we suggest use of a short-term testing system consisting of microbial tests plus mammalian activation
systems (Tier 1), two different Drosophila systems (Tier 2) and four different whole animal systems (Tier
3). The compounds will initially be screened for mutagenicity in Tier 1, and the results obtained in Tier 1
together with what is known about the compound otherwise will dictate the decision whether to continue
the test of the compound in Tier 2 and Tier 3.
Over the past decade the field ofmutagenesis has
experienced widespread growth. This, ofcourse, is
a result ofthe increasing concern over the potential
hazard to man of the chemicals in the environment
and the concern for the future generations as they
may be affected by changes in the genes and
chromosomes ofthe currentgeneration. The major-
ity of this effort has been taking place in the re-
search laboratory where scientists have been at
work devising and developing test systems for de-
tecting chemicals with mutagenic potential. The ef-
fort in the Laboratory of Environmental Mu-
tagenesis has focused primarily in this area; i.e.,
developing new methodology ranging from the
short-term bacterial tests to whole animal tests
which can be used for developing quantitative data
in estimating risks to the human population.
The Mutagenesis Testing Program at the Na-
tional Institute ofEnvironmental Health Sciences is
an outgrowth of the research effort developing
these new systems; because, certainly forthe public
health question, there is a need to do large-scale
testing for a large number ofcompounds which are
already in the environment as well as those new
compounds being added each year. Until recently,
mutagenicity testing was done on preselected com-
pounds in a manner in which the testing laboratory
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knew the identity of the substance under test and
the expected results, that is, positive for com-
pounds selected because of their known car-
cinogenicity and mutagenicity and negative for
compounds such as food additives. There is as yet,
no completed study in which substances were
tested blind by using a preselected standardized
protocol. Also very little attention has been placed
on reproducibility or variability within and between
laboratories utilizing the various test systems which
have developed.
Some ofthese aspects are currently under inves-
tigation in microbial systems by the National
Cancer Institute used as a preselection for com-
pounds for the in vivo bioassay program and by the
Food and Drug Administration, Bureau of Foods,
primarily for the food additives.
Certainly the main endproduct of the NIEHS
Testing Program will be the development ofa facil-
ity and a set ofprotocols for testing a large number
ofchemicals using a tier approach. However, there
are other goals of the program which come along
the way and these primarily focus on the validity, or
some may use the term quality assurance, of the
various test systems employed. The NIEHS Test-
ing Program will utilize a large number of sub-
stances which will all be tested in a blind study.
This will involve the use of a hierarchy of tests
sometimes referred to as the tier approach proceed-
ing from rapid screening in simple, highly sensitive
microbial systems through in vitro mammalian sys-
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tests usually employing mice. Substances which are
found to be mutagenic. im microbial tests would
then be given first priority for additional testing.
Those with negative results would be afforded
lower priorities. However, factors other than the
result of microbial screening will certainly be taken
into account in establishing the testing priority of
each substance. Because of the magnitude of the
task, the eventual goal by 1981 will be to process
1000 compounds a year through the first-stage mi-
crobial tests, and because, as previously stated, one
of the goals of the program is quality assurance of
test systems and laboratories, this program will be
conducted totally as a collaborative research con-
tract.
The first and certainly a very important contract
will be that for chemical management and analysis.
The contractor will be responsible for acquiring,
storing, coding, and dispensing the chemicals which
will be tested in the program. The contractor, with
the assistance of the project officer, will develop a
computerized inventory of the compounds includ-
ing such information as CAS registry number,
Wiswesser line notation, lot number, analytical in-
formation, as well as all information which is cur-
rently available on the toxicity of the material in
question. An extensive amount of physical data on
the compound will also be stored in the computer
for future reference in structure-function analysis.
In the initial phases of the program (the first two
years) the chemicals selected will not be analyzed
for purity. However, subsequent to testing when
positive results are obtained (especially when posi-
tive results are obtained in the microbial system but
are not verified in other systems), chemical
analyses will be conducted to identify that fraction
of the material tested having the mutagenic proper-
ties. That is, a positive result in the microbial test
may be due to its extreme sensitivity to low quan-
tities ofimpurities in the material. Ofthe three tiers
to be employed, only those systems in the first tier
have at this time been selected. Testing will be con-
ducted using several of the different Salmonella
strains in which reverse mutations are detected in
the histidine locus and E. coli in which DNA repair
is detected.
It is anticipated that two separate contracts will
be awarded during this first year to conduct the
microbial tests. There will be a certain percentage,
of overlap of compounds sent to the two
laboratories and, additionally, another percentage
ofcompounds will be sent to the same laboratory at
two different intervals; hence, we will be able to
obtain quality assurance information both within
and between laboratories. And, ofcourse, certainly
in this first phase of the program a significant per-
centage of the compounds sent will be known
mutagens.
While the systems for the second and third tier
have not yet been finally selected, at the present
time it seems rather certain that the recessive le-
thals and heritable translocations as measured in
Drosophila will be employed. Also in the second
year, mammalian cells in tissue culture will be em-
ployed. Exactly which system will be used is not
yet certain although the current available informa-
tion would tend to favor either the Chinese hamster
cells or the mouse lymphoma cell system. Both re-
cessive lethals and heritable translocations in
Drosophila are tests which have been utilized in
research laboratories for many years and their re-
liability is thought to be high as well as offering
relatively inexpensive processing.
The tier 3 or whole-animal tests selections are
more in doubt at this point in time. There is a sig-
nificant amount ofwork being done in this area and,
of course, this part of the program will not com-
mence for probably two more years. Hence, it
would be unwise to make a selection at this time. It
is, ofcourse, clear to use those tests which measure
chromosomal aberrations and tests which measure
gene mutations. Currently the heritable transloca-
tion test in the mouse seem to offer advantages be-
cause as a whole animal test, it is relatively cheap
and it provides a clear cut detection of genetic
events which are definitely transmitted to the
offspring. Chromosome breakage has been demon-
strated to be a function of many mutagenic agents,
and while the bearers of reciprocal translocations
often have a normal phenotype, a high percentage
oftheir offspring are expected to have duplications
and deficiences for genetic material. In humans this
has been shown to give rise to fetal loss, unbalanced
genome effects and trisomes like Down's Syn-
drome.
The only method which has received wide usage
for detecting gene mutations in mammals is the
specific locus test first employed by Dr. Russell in
radiation mutagenesis some 25 years ago. There
are, however, efforts underway in several
laboratories to develop additional gene mutation as-
says which detect mutations at loci which code for
various enzymes. One of the advantages of these
systems is that they will sample more loci in the
genome and hence, it is expected, will give a more
reliable estimate of an induced mutation frequency.
An additional advantage is that since these are en-
zymes which are common to a large number of or-
ganisms, including humans, while the metabolic dif-
ferences between the mouse and human still exists,
at least the enzyme detection will be at genes of
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We will be working very closely with the statisti-
cians and the computer people to provide both for
adequate design and for computer capabilities for
handling and analyzing all ofthe data from the vari-
ous test systems. It is becoming increasingly clear
that the management ofdata for mutagenesis testing
is becoming tremendously complex and the only
logical way to handle such data is by a computer.
I have described the reasons and the background
behind establishing the mutagenesis program at
NIEHS and have provided a brief outline of the
methods which we intend to employ to establish
this program. However, I have failed to mention
the one area which to many ofyou is aquestion high
in your mind; and that is what compounds are going
to be tested in the NIEHS Testing Program. At the
present time we do not have an answer to that ques-
tion. However, I can describe to you the system
that we intend to utilize to select the compounds.
We will establish a committee at NIEHS in coor-
dination with compound selection committees in
the other Federal agencies. This committee will be
charged with first establishing a selection ofcriteria
for classes of compounds for testing. The selection
criteria could be, for instance, production quantity,
level of exposure to man, structural relationship to
other mutagens, and various other criteria; and then
secondly the committee will select compounds for
test upon these criteria. It is anticipated at this time,
although not at all definite, that NIEHS will adver-
tise for nominations for compounds to be selected
for testing in our program. This mechanism is cur-
rently operative at other Federal agencies. Since
NIEHS neither has a regulatory function nor is
oriented toward a single environmental disease, it is
logical to assume that we will be looking at a wide
variety of compounds.
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